Loading
Pasritamig is Johnson & Johnson's bispecific T-cell engager that binds KLK2 on prostate cancer cells and CD3 on T cells, with a deliberately low-affinity CD3 arm. In phase 1 about 40% of patients had a PSA50 response with far less cytokine release syndrome than other engagers, and a phase 3 trial began in 2025.
Pasritamig (JNJ-78278343) is a bispecific T-cell engager that binds KLK2 on prostate cancer cells and CD3 on T cells; a deliberately low-affinity CD3 arm limits cytokine release so that it can be given in the outpatient setting. It is being developed for metastatic castration-resistant prostate cancer after an androgen receptor pathway inhibitor, with or without a prior taxane. In phase 1, about 40% of patients achieved a PSA50 response at the recommended dose, with cytokine release syndrome rates far below other engagers, and the phase 3 KLK2-P3-01 trial began in 2025. Whether PSA responses will translate into radiographic and survival benefit, and how durable responses are, remain open. For a newcomer, it is Johnson & Johnson's prostate-specific T-cell engager, notable for how little cytokine storm it caused in early trials.
Backbone ribbon from PDB 1IGT. RCSB PDB 1IGT. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
No public structure of pasritamig; representative IgG shown.
Low-affinity CD3 arm and KLK2 targeting; designed for outpatient dosing. Connects to KLK2 (kallikrein-2) and CD3.
1.One arm of Pasritamig binds KLK2 (kallikrein-2) on the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pasritamig" OR ABSTRACT:"Pasritamig" OR TITLE:"JNJ-78278343" OR ABSTRACT:"JNJ-78278343") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pasritamig, not a curated reading list.
Shares CD3, Cytokine release syndrome (CRS), T-cell engagers (bispecific), Metastatic castration-resistant prostate cancer.
Shares CD3, T-cell engagers (bispecific), Prostate cancer.
Shares Johnson & Johnson, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Johnson & Johnson, Prostate cancer.
Shares Johnson & Johnson, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Cytokine release syndrome (CRS), T-cell engagers (bispecific).
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.